The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells
These results indicate that ruxolitinib, inhibiting the release of several mediators from human basophils and mast cells, is a potential candidate for the treatment of inflammatory disorders.
Authors
- Caterina Strisciuglio (ORCID: https://orcid.org/0000-0002-9005-6571)
- Gianluca Lagnese (ORCID: https://orcid.org/0000-0001-9504-429X)
- Antonio di Salvatore (ORCID: https://orcid.org/0000-0002-6434-3112)
- Remo Poto (ORCID: https://orcid.org/0000-0002-4723-0167)
- Leonardo Cristinziano (ORCID: https://orcid.org/0000-0002-7835-2212)
- Gjada Criscuolo (ORCID: https://orcid.org/0000-0002-5928-1869)
- Francesco Palestra (ORCID: https://orcid.org/0000-0001-6145-7475)
- Gilda Varricchi (ORCID: https://orcid.org/0000-0002-9285-4657)
- Stefania Loffredo (ORCID: https://orcid.org/0000-0002-5871-1898)
- Giuseppe Spadaro (ORCID: https://orcid.org/0000-0001-7889-425X)
- Gianni Marone (ORCID: https://orcid.org/0000-0002-9849-4701)
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- Istituto Superiore di Sanità (IT)
- Institute for Experimental Endocrinology and Oncology (IT)
- National Research Council (IT)
- World Health Organization - Italy (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-08-12
- DOI
- https://doi.org/10.3389/fimmu.2024.1443704
- Citations
- 14
- Primary Topic
- Mast cells and histamine
- Type
- article
- Field-Weighted Citation Impact
- 3.37
Funders
- Università degli Studi di Napoli Federico II
- Regione Campania